{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Southwell JW"],"funding":["Deutsche Forschungsgemeinschaft","Fonds der Chemischen Industrie","University of York","Engineering and Physical Sciences Research Council"],"pagination":["e202202536"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10108276"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(8)"],"pubmed_abstract":["Due to rising resistance, new antibacterial strategies are needed, including methods for targeted antibiotic release. As targeting vectors, chelating molecules called siderophores that are released by bacteria to acquire iron have been investigated for conjugation to antibacterials, leading to the clinically approved drug cefiderocol. The use of small-molecule catalysts for prodrug activation within cells has shown promise in recent years, and here we investigate siderophore-linked ruthenium catalysts for the activation of antibacterial prodrugs within cells. Moxifloxacin-based prodrugs were synthesised, and their catalyst-mediated activation was demonstrated under anaerobic, biologically relevant conditions. In the absence of catalyst, decreased antibacterial activities were observed comp"],"journal":["Chemistry (Weinheim an der Bergstrasse, Germany)"],"pubmed_title":["Siderophore-Linked Ruthenium Catalysts for Targeted Allyl Ester Prodrug Activation within Bacterial Cells."],"pmcid":["PMC10108276"],"funding_grant_id":["GRK 2341","EP/L024829/1","EP/T007338/1"],"pubmed_authors":["Raines DJ","Southwell JW","Seefeldt J","Schubert N","Dreher T","Gutenthaler SM","Duhme-Klair AK","Thomas GH","Herman R","Clarke JE","Metzler-Nolte N","Wilson KS","Boswald I"],"additional_accession":[]},"is_claimable":false,"name":"Siderophore-Linked Ruthenium Catalysts for Targeted Allyl Ester Prodrug Activation within Bacterial Cells.","description":"Due to rising resistance, new antibacterial strategies are needed, including methods for targeted antibiotic release. As targeting vectors, chelating molecules called siderophores that are released by bacteria to acquire iron have been investigated for conjugation to antibacterials, leading to the clinically approved drug cefiderocol. The use of small-molecule catalysts for prodrug activation within cells has shown promise in recent years, and here we investigate siderophore-linked ruthenium catalysts for the activation of antibacterial prodrugs within cells. Moxifloxacin-based prodrugs were synthesised, and their catalyst-mediated activation was demonstrated under anaerobic, biologically relevant conditions. In the absence of catalyst, decreased antibacterial activities were observed comp","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-04T20:18:01.733Z","creation":"2025-04-04T20:18:01.733Z"},"accession":"S-EPMC10108276","cross_references":{"pubmed":["36355416"],"doi":["10.1002/chem.202202536"]}}